CATALOGO DEI PRODOTTI DELLA RICERCA

PILOTTO, Sara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.205
EU - Europa 4.382
AS - Asia 4.104
SA - Sud America 586
AF - Africa 96
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 6
AN - Antartide 1
Totale 14.389
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.107
SG - Singapore 1.675
CN - Cina 1.348
GB - Regno Unito 1.008
IT - Italia 579
HK - Hong Kong 555
DE - Germania 545
BR - Brasile 514
RU - Federazione Russa 449
SE - Svezia 435
FR - Francia 374
IE - Irlanda 370
FI - Finlandia 279
KR - Corea 154
VN - Vietnam 100
NL - Olanda 98
PL - Polonia 57
CA - Canada 53
UA - Ucraina 46
JP - Giappone 42
TG - Togo 42
ID - Indonesia 36
IN - India 35
AT - Austria 32
BE - Belgio 27
TR - Turchia 25
MX - Messico 23
ES - Italia 19
CZ - Repubblica Ceca 17
AR - Argentina 15
MA - Marocco 15
BD - Bangladesh 14
IR - Iran 13
VE - Venezuela 13
CO - Colombia 12
ZA - Sudafrica 12
UZ - Uzbekistan 11
IQ - Iraq 9
PK - Pakistan 9
AZ - Azerbaigian 8
CL - Cile 8
KZ - Kazakistan 8
PE - Perù 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
CH - Svizzera 7
EC - Ecuador 7
LT - Lituania 7
PH - Filippine 6
EU - Europa 5
HN - Honduras 5
LV - Lettonia 5
NP - Nepal 5
PY - Paraguay 5
SA - Arabia Saudita 5
TN - Tunisia 5
CR - Costa Rica 4
DK - Danimarca 4
EG - Egitto 4
KG - Kirghizistan 4
KH - Cambogia 4
LA - Repubblica Popolare Democratica del Laos 4
LK - Sri Lanka 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
AO - Angola 3
JM - Giamaica 3
JO - Giordania 3
NO - Norvegia 3
PA - Panama 3
PS - Palestinian Territory 3
PT - Portogallo 3
TW - Taiwan 3
BG - Bulgaria 2
BM - Bermuda 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GR - Grecia 2
IL - Israele 2
KE - Kenya 2
LU - Lussemburgo 2
LY - Libia 2
MY - Malesia 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BY - Bielorussia 1
CY - Cipro 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
GM - Gambi 1
GP - Guadalupe 1
GS - Georgia del Sud e Isole Sandwich Australi 1
GT - Guatemala 1
IM - Isola di Man 1
ME - Montenegro 1
MG - Madagascar 1
MW - Malawi 1
Totale 14.376
Salva come PNG Salva come JPEG
Città #
Southend 901
Dallas 833
Chandler 819
Singapore 744
Hong Kong 547
Dublin 369
Ashburn 354
Woodbridge 298
Beijing 279
Munich 269
Jacksonville 195
Ann Arbor 181
Verona 153
New York 134
Lawrence 125
Princeton 125
Wilmington 114
Helsinki 106
The Dalles 104
Jinan 103
Houston 74
Turku 70
Sindelfingen 64
Los Angeles 63
Shenyang 60
Redmond 59
Tianjin 55
Nanjing 54
Columbus 50
Hebei 50
Seoul 47
Milan 46
Santa Clara 44
Lomé 42
São Paulo 42
Seattle 40
Tokyo 37
Washington 34
Jakarta 32
Nanchang 32
Kent 31
Zhengzhou 31
Guangzhou 30
Nuremberg 30
San Francisco 30
Frankfurt am Main 29
Haikou 29
Hangzhou 29
Brussels 27
Changsha 27
London 27
Ningbo 27
Boardman 25
Council Bluffs 25
Brooklyn 23
Rome 23
Amsterdam 22
Dong Ket 22
Lappeenranta 21
Chicago 20
Taiyuan 20
Taizhou 20
Moscow 19
Vienna 19
Falls Church 18
Hanoi 17
Jiaxing 17
Redwood City 16
Warsaw 16
Belo Horizonte 15
Toronto 15
Atlanta 14
Fuzhou 14
Ho Chi Minh City 14
Norwalk 13
Rio de Janeiro 13
Bologna 12
Brno 12
Stockholm 12
Augusta 11
Falkenstein 11
Lanzhou 11
Maceió 11
Porto Alegre 11
Tashkent 11
Johannesburg 10
Montreal 10
Ottawa 10
Padova 10
Phoenix 10
Denver 9
Lancaster 9
Mexico City 9
Shanghai 9
Trento 9
Vicenza 9
Boston 8
Chennai 8
Curitiba 8
San Mateo 8
Totale 8.774
Salva come PNG Salva come JPEG
Nome #
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 216
Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis 182
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 170
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 168
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 154
ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations 151
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 147
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 143
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 143
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 141
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 141
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 133
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 132
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 129
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 126
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 125
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 125
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 124
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 124
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 120
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 120
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 119
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 116
Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting 110
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 108
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 108
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 108
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 106
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 104
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 102
Clinical meta-analyses of targeted therapies in adenocarcinoma. 101
Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research 101
A multimodal approach to cancer-related cachexia: from theory to practice 101
A Feasibility Study Investigating an Exercise Program in Metastatic Cancer Based on the Patient-Preferred Delivery Mode 100
Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival 100
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 100
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 100
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 99
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 98
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC 98
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned 98
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 97
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 97
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 96
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 96
Potential role of RICTOR copy number gain (CNG) as a key biomarker of mTOR activity: A comprehensive preclinical analysis in squamous cell lung cancer (SQLC) models 95
Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer 94
MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy 94
Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease 94
Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer 94
Do immune checkpoint inhibitors need new studies methodology? 93
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 93
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 93
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 91
Exercise levels and preferences in cancer patients: a cross-sectional study 91
Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis 89
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 89
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 89
Targeting the epidermal growth factor receptor in solid tumors: focus on safety. 88
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies 88
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 88
Abscopal effect and resistance reversion in nivolumab-treated non-small-cell lung cancer undergoing palliative radiotherapy: a case report 88
Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer 87
Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity 86
Muscle derangement and alteration of the nutritional machinery in NSCLC 86
Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients 86
A cross-sectional study evaluating the exercise discussion with oncologist during cancer consultation: the CONNECT study 85
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 85
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 85
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 84
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 84
Platelet-derived growth factor receptor inhibitors for non-small cell lung cancer: is the odyssey over? 82
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 82
Genetic, epigenetic and micro-environmental markers as predictors of prognosis, response and resistance to chemotherapy, targeted agents and immunotherapy in resected squamous cell lung carcinoma (SQLC). 81
Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'? 80
Tracking occult pN2 disease after mediastinal dissection in early stage lung cancer. 80
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 80
Exercise for counteracting post-acute COVID-19 syndrome in patients with cancer: an old but gold strategy? 80
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer 79
Physical activity and exercise in lung cancer care: will promises be fulfilled? 79
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option? 79
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 79
Exercise and anemia in cancer patients: could make the difference? 77
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done 75
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 75
Nurses' perspectives on physical activity promotion in cancer patients: A qualitative research 75
A qualitative study exploring the experiences and perspectives of patients with cancer attending a 12-week exercise program 74
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials 74
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 73
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy 73
Evidence-based tailored nutrition educational intervention improves adherence to dietary guidelines, anthropometric measures and serum metabolic biomarkers in early-stage breast cancer patients: A prospective interventional study 72
Cellular and molecular biology of small cell lung cancer: an overview 71
Molecular Bases for Combinatorial Treatment Strategies in Patients with KRAS Mutant Lung Adenocarcinoma and Squamous Cell Lung Carcinoma 71
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis 71
Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities 71
Exercise oncology: It is time to make a change 71
Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications 70
Kinesiology students' perception regarding exercise oncology: a cross-sectional study 70
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. 70
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities 70
Totale 9.980
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.731
article - articoli 66.346
book - libri 0
conference - conferenze 844
curatela - curatele 0
other - altro 253
patent - brevetti 0
selected - selezionate 0
volume - volumi 288
Totale 135.462
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021596 0 0 35 112 99 88 29 16 24 24 122 47
2021/20221.080 60 292 8 119 39 27 31 58 46 23 95 282
2022/20232.327 144 261 206 411 196 539 19 137 262 21 97 34
2023/20241.661 59 95 158 166 212 267 99 139 39 117 229 81
2024/20254.541 230 184 209 791 148 200 201 192 708 351 435 892
2025/20262.214 848 732 634 0 0 0 0 0 0 0 0 0
Totale 14.696